A major NHS trial of the Galleri blood test has not met its main objective, according to its developer, Grail. The test, which is being evaluated in around 142,000 patients, aims to detect up to 50 types of cancer through a simple blood sample — often before symptoms appear. The trial was designed to determine whether the test could reduce…
Ben KempMarch 2, 2026